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Abstract: In the last half-century, the development of biodegradable polymeric materials 
for biomedical applications has advanced significantly. Biodegradable polymeric materials 
are favored in the development of therapeutic devices, including temporary implants and 
three-dimensional scaffolds for tissue engineering. Further advancements have occurred in 
the utilization of biodegradable polymeric materials for pharmacological applications such as 
delivery vehicles for controlled/sustained drug release. These applications require particular 
physicochemical, biological, and degradation properties of the materials to deliver effective 
therapy. As a result, a wide range of natural or synthetic polymers able to undergo hydrolytic 
or enzymatic degradation is being studied for biomedical applications. This review outlines the 
current development of biodegradable natural and synthetic polymeric materials for various 
biomedical applications, including tissue engineering, temporary implants, wound healing, 
and drug delivery.
Keywords: tissue engineering, drug delivery, wound healing, natural biomaterials, synthetic 
biomaterials
Introduction
A biomaterial can be defined as a material intended to interface with biological 
systems in order to evaluate, treat, augment, or replace any tissue, organ, or func-
tion of the body.1 The global market for implantable biomaterials was worth nearly 
$75.1 billion in 2013. This market is expected to grow at a compound annual growth 
rate (CAGR) of 6.7% between 2014 and 2019, resulting in a $79.1 billion global 
market in 2014 and a $109.5 billion global market in 2019.2 Although biomedical 
applications of natural enzymatically degradable polymers date back thousands of 
years, the application of synthetic biodegradable polymers began only in the second 
half of the 1960s.3 Considering their advantages over biostable materials in terms of 
long-term biocompatibility along with the technical and ethical issues accompanying 
revision surgeries, investigations into the application of biodegradable biomaterials 
rather than permanent prosthetic devices for assisting in tissue repair and regen-
eration has vigorously increased recently.4–6 As a result, polymeric biomaterials are 
quickly replacing other material classes, such as metals, alloys, and ceramics, for use 
as biomaterials due to their versatility.3–5 Within the global implantable biomaterial 
market, the polymeric biomaterials sector is expected to show the highest growth, at 
a CAGR of 22.1%, because of its promising potential in a wide range of biomedical 
applications.2 With this in mind, the aim of this review is to highlight the most often 
studied polymeric biomaterials and underscore their immense potential in the areas 
of drug design, development, and therapy.
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A critical requirement for a biomaterial is biocompatibility – 
the ability of a material to function with an appropriate host 
response in a specific application.1 Many biological and 
physicochemical characteristics of an implant material 
govern the host tissue response to the material. For instance, 
molecular weight, solubility, hydrophilicity/hydrophobicity, 
surface energy, material chemistry, mechanism of degrada-
tion and/or erosion, lubricity, and shape and structure of the 
implant can all influence the material’s biocompatibility.7 
Importantly, a biodegradable biomaterial requires excellent 
biocompatibility over time because the physicochemical, 
mechanical, and biological properties of a biodegradable 
biomaterial will differ with time and, thus, the resulting 
degradation products can possess varying levels of tissue 
compatibility as compared with the initial parent material. 
An ideal biodegradable biomaterial should have degrada-
tion products that are nontoxic and easily metabolized and 
cleared from the body.
In addition to biocompatibility, several other important 
properties must be considered when choosing a biodegrad-
able biomaterial. First, the degradation time of the biomate-
rial should coincide with the regeneration and/or healing 
process to ensure proper remodeling of the tissue. Second, 
the biomaterial must maintain suitable permeability and 
processability for its intended application. Finally, the 
mechanical properties of the biomaterial should be suffi-
cient to promote regeneration during the patient’s everyday 
activities, and any change in mechanical properties due to 
degradation should preserve compatibility with the healing 
or regeneration process.
Given the complexity of the human body and the scope 
of applications that polymeric biomaterials are currently 
utilized for, no single polymeric system can be considered 
the ideal biomaterial for all medical applications. Thus, 
recent advances in biodegradable biomaterial synthesis have 
been directed toward developing and synthesizing polymers 
with properties tailored for specific biomedical applications. 
Moreover, current developments incorporating multifunc-
tional and combinatorial approaches in biomaterial design 
have accelerated the innovation of novel biodegradable 
biomaterials. Another hotspot in biomaterials research is the 
development of therapeutic devices, including temporary 
prostheses, three-dimensional (3D) porous scaffolds for 
tissue engineering, and delivery vehicles for pharmacological 
applications. Most recently, 3D bioprinting has also been 
acknowledged, and preliminary data collection for biomate-
rial use as potential bio-ink for printing of 3D scaffolds have 
begun. Because biodegradable biomaterials exhibit a variety 
of biological and physicochemical properties and, therefore, 
can replicate the properties of different tissues, these mate-
rials are assessed for use as 1) large implants, including 
bone screws, bone plates, and contraceptive reservoirs; 
2) small implants, in the form of sutures and staples; 3) plain 
membranes for guided tissue regeneration; and 4) porous 
structures or multifilament meshes for tissue engineering.8 
Moreover, by properly engineering the structure and degrada-
tion parameters, these biodegradable materials can be used 
to generate micro- or nanoscale drug-delivery vehicles for 
controlled drug delivery in an erosive or diffusive manner, 
or as a combination of both.9
Because of the interest aroused in the areas demanding 
biodegradable biomaterials, including regenerative medicine, 
tissue engineering, controlled drug delivery, gene therapy, 
and nanotechnology, there has been a robust expansion of 
biomedical applications of synthetic biodegradable polymers 
and analogous natural polymers, and our review will focus on 
exploring the most current development of these polymers 
for biomedical applications in these fields. Although many 
other reviews have focused on the topic of biodegradable 
biomaterials for medical use, to our best knowledge, there 
has not been a review published within the past 5 years that 
covers as much breadth as our review does about the devel-
opment of the most commonly investigated biodegradable 
polymeric biomaterials in the fields of drug delivery, tissue 
engineering, and wound application.
Natural biodegradable polymeric 
biomaterials
Biodegradable biomaterials can be roughly divided into two 
categories – natural and synthetic – based on their source and 
whether they are composed of naturally occurring extracel-
lular matrix (ECM). Natural biodegradable polymeric bio-
materials generally include proteins (collagen, fibrin, silk, 
etc.), and polysaccharides (starch, alginate, chitin/chitosan, 
hyaluronic acid derivatives, etc.).10–12 Furthermore, a family 
of native polyesters – polyhydroxyalkanoates (PHA) – has 
been recognized as natural biodegradable biomaterials and, 
more recently, sundew adhesives (natural polysaccharide-
based hydrogels) and ivy nanoparticles (macromolecular 
compositions of nanospherical arabinogalactan proteins) 
have garnered more attention for their ability to create effec-
tive nanocomposite adhesives and for their potential use as 
nano-carriers in drug delivery, respectively.13,14
Collagen
As the most prevalent protein in the human body, collagen 
offers physical support to tissues by inhabiting the intercel-
lular space, acting not only as native structural support for 
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organizing cells within connective tissues, but also as a 
mobile, dynamic, and flexible substance essential to cellular 
behaviors and tissue function.15 Generally, collagen is a rod-
type polymer approximately 300-nm long with a molecular 
weight of approximately 300 kDa. Free amino acids in the 
body are synthesized into subunit chains of collagen, which 
then undergo transcription, translation, and post-translational 
modification processes in suitable cells such as osteoblasts 
and fibroblasts.13 More than 22 different types of collagen 
have been identified in the human body, with types I–IV 
being the most common, and type I collagen being the single 
greatest abundant protein present in mammals.15 Collagen 
undergoes enzymatic degradation within the body by a 
diverse set of enzymes, such as matrix metalloproteinases and 
collagenases, to yield its corresponding amino acids. Due to 
its enzymatic degradability; unique mechanical, biological, 
and physicochemical properties; nontoxicity; and high tensile 
strength, collagen has been widely studied for biomedical 
applications.16,17
Collagen plays a critical role in preserving the biological 
and structural integrity of the ECM and is highly dynamic, 
undergoing continuous remodeling for proper physiologic 
functions. For most soft and hard connective tissues (eg, 
blood vessels, cornea, skin, tendon, cartilage, and bone), 
collagen fibrils and their networks function through their 
highly organized 3D structure. Tissue regeneration attempts 
to repair both the structural integrity and the intricate remod-
eling process of the native ECM, particularly restoring the 
delicate collagen networks under which normal physiologic 
regeneration occurs; thus, recent efforts have been focused 
on replacing native collagen-based ECM by developing 
novel biomaterials that imitate its intricate fibrillar archi-
tecture and function as cell scaffolding. Animal-derived 
and recombinant collagens, especially type I collagen, are 
recognized as one of the most valuable biomaterials available 
and are now extensively used for tissue engineering, drug 
delivery, and cosmetic surgery. For example, a composite of 
fibrillar collagen, hydroxyapatite, and tricalcium phosphate 
(Collagraft®, Angiotech Pharmaceuticals) has been approved 
by the United States Food and Drug Administration (FDA) 
as a biodegradable synthetic bone graft substitute.18
The main sources of collagen presently utilized for bio-
medical applications are bovine or porcine skin and bovine 
or equine Achilles tendons. They are utilized in either their 
native fibrillar form or after denaturation in various fabricated 
forms, such as sponges, sheets, plugs, and pellets. Collagen-
based materials have been successfully used for skin repair.19 
For example, Promogran® (Systagenix) – a spongy collagen 
matrix containing oxidized cellulose – is available in the USA 
and Europe for treatment of diabetic and ulcer wounds.20 
Similarly, an FDA-approved bilayer skin substitute (Integra® 
Dermal Regeneration Template, Integra LifeSciences) com-
posed of a dermal layer of cross-linked bovine collagen and 
glycosaminoglycans (GAGs) as well as an epidermal layer 
of polysiloxane, which deposits ECM components, is in the 
market for full-thickness or deep partial thickness thermal 
injury. Moreover, these skin substitutes constructed from 
cell-seeded collagens have been widely commercialized 
(eg, Apligraf®, Organogenesis, Inc.) and (OrCel™, Ortec 
International Inc.). Interestingly, type I collagen sponges 
have also been used to engineer patellar tendons in rabbits 
under different culture conditions.21–23 Using the collagen 
sponge combined with bone marrow-derived mesenchymal 
stem cells, Juncosa-Melvin et al demonstrated that the engi-
neered tendon tissue attained almost 75% of the mechanical 
properties of native tendon.22 In other studies, collagen has 
also been successfully used as a scaffold in nerve and bladder 
engineering.24–26 Additionally, a suture-free, 3D-collagen 
matrix graft – DuraGen® (Integra LifeSciences) – has been 
developed for spinal dural repair and regeneration and is 
currently approved by the FDA.27
Collagen is, furthermore, a key initiator of the coagulation 
cascade and, therefore, it has been successfully developed as 
a hemostatic agent due to its high thrombogenicity. Multiple 
collagen-based hemostats are currently available or undergo-
ing clinical trials for a variety of surgical indications; these 
include Sulzer-Spine® Tech’s sealants composed of bovine 
collagen and bovine thrombin for cardiovascular and spinal 
surgical procedures; Floseal® (Baxter Healthcare), a high-
viscosity gel hemostatic agent composed of collagen-derived 
particles and topical bovine-derived thrombin; and CoStasis® 
Surgical Hemostat (Cohesion Technologies), which consists 
of bovine thrombin and bovine microfibrillar collagen com-
bined with autologous plasma.
With regard to drug delivery, collagen has been notably 
studied for the delivery of low-molecular-weight drugs, 
proteins, genes, and plasmids. Currently, a few collagen-
based gentamicin-delivery vehicles are available in the global 
market (eg, Sulmycin®-Implant and Collatamp®-G, Innocoll 
Pharmaceuticals Ltd). These delivery systems permit a 
sustained local delivery of antibiotics with limited systemic 
exposure. Moreover, another product, Septocoll® (Biomet), 
achieved prolonged collagen delivery by incorporating two 
gentamicin salts possessing different solubility, and has 
been approved for infection prevention.28 More recently, a 
new biodegradable, collagen-based chlorhexidine chip has 
been shown to provide a longer, more sustained release of 
chlorhexidine in the confines of the periodontal pocket as 
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compared to simple subgingival irrigation of chlorhexidine. 
The constant outflow of the gingival crevicular fluid from 
the periodontal pocket (up to 40 times an hour) renders 
subgingival irrigation of chlorhexidine useless in delivering 
significant antimicrobial benefits, reduction in probing 
depths, and clinical attachment level gain to manage chronic 
periodontitis; however, the use of a collagen-based release 
vehicle allows for a controlled delivery of chlorhexidine 
to achieve the intended pharmaceutical effects.29 Further-
more, current clinical trials are investigating cross-linked, 
absorbable collagen sponges as protein-carrier vehicles. 
Prolonged release of bioactive proteins, such as recombi-
nant human bone morphogenic protein-2 (rhBMP-2), have 
been reported when utilized in conjunction with collagen 
matrices due to desirable interactions of the collagen matrix 
with the protein.30 This combination product is approved 
by the FDA for simultaneous use with a titanium interbody 
spine fusion cage for anterior lumbar spinal fusion (InFUSE® 
Bone Graft/LT-CAGE® Lumbar Tapered Fusion Device, 
Medtronic Spinal and Biologics), and a similar product 
InductOs® (Medtronic Spinal and Biologics) is approved 
in Europe for the treatment of acute tibial fractures in adult 
patients. Additionally, a recent study reported that the deliv-
ery of rhBMP-2 by an absorbable collagen sponge stimulated 
bone reconstruction in advanced alveolar ridge defects.31 
Aside from its use as a protein-delivery vehicle, collagen 
has been demonstrated to retain gene vector/plasmid DNA 
whereas simultaneously protecting it from enzymatic or 
immunological reactions of the body, which underscores its 
potential in gene and plasmid DNA delivery.32
One disadvantage of these collagen-based biomaterials 
is their mild immunogenicity due to the antigenic sites in the 
central helix and the composition of the terminal region, which 
significantly limits their clinical application.33 The immune 
response varies depending on the processing techniques, site 
of implantation, and species from which the collagen has 
been isolated.34 Other disadvantages of animal-derived col-
lagen include the varying physicochemical and degradation 
properties, the high cost of pure collagen, and the allogeneic 
or xenogeneic sources, which increase the risk of infectious 
disease transmission. In response to these limitations, pres-
ent investigations have directed focus toward recombinant 
systems that can produce human-based collagen.35,36 Several 
potentially useful systems already exist for large-scale pro-
duction and purification of recombinant collagen, such as 
yeasts, transgenic animals, and, most recently, Escherichia 
coli.37,38 Because the amino acid sequence of recombinant 
collagen can be directly modified, it is possible to make 
controlled, targeted collagen products for specific applica-
tions, thereby diversifying and increasing the potential of 
collagen-based products.39 However, recombinant collagen 
is unable to undergo natural posttranslational modification 
and, thus, may lack critical biological activities of native 
tissue.33 This lack of posttranslational modification means 
that, despite its flexibility in creating countless different 
amino acid sequences for different targeted applications, 
recombinant collagens may not be suitable for many biomedi-
cal applications, especially those that require stability and 
strength such as heart valves. Furthermore, the commercially 
available recombinant collagens are still expensive to pro-
duce and, thus far, only limited amounts are available.39
Collagen as a biomaterial has already seen significant 
use in several specific applications in skin repair, hemostatic 
agents, and drug delivery, but its slight immunogenicity, high 
cost, and varying physicochemical and degradation properties 
prevent further expansion of collagen-based biomaterials. 
Although recombinant collagens have the potential to 
catapult collagen-based biomaterials for widespread use, 
significant limitations such as their lack of posttranslational 
modification will need to be continually studied for them to 
have any noticeable impact for use as a biomaterial.
Gelatin
Gelatin is a natural biopolymer derived from collagen via 
controlled alkaline, acid, or enzymatic hydrolysis.40 As a 
result of its biological origin, it has excellent biodegrad-
ability and biocompatibility and because it is widely avail-
able, gelatin is a relatively low-cost polymer.40 Gelatin has 
been used in medical and pharmaceutical fields as a matrix 
for implants, and as stabilizers in vaccines such as measles, 
mumps, and rubella.41 Moreover, gelatin is water permeable 
and soluble in water and has multifunctional properties as 
a drug-delivery carrier.42 Gelatin’s mechanical properties, 
swelling behavior, thermal properties, and many other phys-
iochemical properties can be dependent upon the collagen 
source, extraction method, amount of thermal denatured 
employed, and the degree of cross-linking, thereby making 
gelatin a very versatile polymer.43 Furthermore, its ability to 
produce a thermoreversible gel makes it a very good candi-
date as a targeted drug-delivery carrier and, as a result, gelatin 
can be utilized to develop specific drug-release profiles, 
allowing for a broad range of applications in drug delivery.43
Gelatin is a versatile biopolymer that traditionally enabled 
the design of several different drug carrier systems, such as 
microparticles, nanoparticles, fibers, and hydrogels.44 Each 
of these different systems has certain properties that make 
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them particularly suitable for drug delivery.44 For example, 
gelatin microparticles are popular for serving as vehicles for 
cell amplification and delivery of large bioactive molecules, 
and gelatin nanoparticles are better for drug delivery to the 
brain or in intravenous delivery.44 Recently, a novel and 
relatively simple method was discovered for producing 
gelatin microparticles which allow for very high protein- and 
drug-loading efficiencies.45 In the experiment, bovine serum 
albumin (BSA) was added at a 0.1%–0.4% gelatin concentra-
tion, resulting in a gelatin solution.45 The solution was freeze-
dried and the resulting spongy membranes were hardened 
with liquid nitrogen and subsequently ground to a powder, 
producing BSA-loaded microparticles in random forms and 
shapes.45 These microparticles were then incorporated into 
porous scaffolds constructed of polylactide (PLLA) and poly-
caprolactone (PCL).45 The in vitro release profile of the protein 
from the particles alone and from the particle-incorporated 
scaffolds demonstrated up to 90% protein-loading efficiency, 
showing that BSA-loaded microparticles in conjunction with 
particle-incorporated scaffolds for growth factor release 
may be possible for application in bone tissue engineering.45 
Another study studied the in vitro efficacy and toxicity of 
incorporating polyenes into electrospun gelatin fiber mats 
as a topical antifungal application.46 The research group 
found that polyene-loaded antifungal gelatin mats displayed 
better antifungal activity than using traditional electrospun 
gelatin fiber mats.46 Furthermore, they found that polyenes 
stabilized the triple helical conformation of gelatin whereas 
gelatin decreased the hemolytic activity of polyenes, making 
polyene antifungal-loaded gelatin fiber mats a possibility in 
managing superficial skin infections in the future.46 Cohen 
et al studied novel tissue adhesives based on gelatin, with 
alginate as a polymeric additive, loaded with bupivacaine or 
ibuprofen for pain management.47 They found that the release 
of drugs from the adhesive matrix was primarily controlled 
by the gelatin/alginate bioadhesive’s characteristics, such 
as swelling and hydrophilic group concentrations that can 
be adjusted by changing the ratio of gelatin to alginate.47 
Moreover, they found that the hydrophilicity and electrical 
interactions between bupivacaine and ibuprofen with the 
adhesive components had some effect on the release profile 
of the drug, and that incorporating bupivacaine improved 
the bonding strength of the adhesive due to its inert nature 
whereas ibuprofen decreased the bonding strength due to its 
reactive nature with the alginate/gelatin adhesive.47 Overall, 
the study shows that this loading bupivacaine in a gelatin/
alginate bioadhesive can potentially be used for wound-
closing applications.47
The primary advantages of gelatin are its biodegrad-
ability, availability, and cheap cost.44 Porcine skin-derived 
gelatin is the most popular source, followed by bovine skin, 
and bone.48 However, religious issues may arise, as porcine-
derived products and bovine-derived products are forbidden 
in Judaism and Hinduism, respectively.48 In addition, there 
are health concerns over transmission of pathogenic vectors 
such as prions.48 Recombinant gelatins, however, can be 
utilized to overcome the disadvantages with animal tissue-
derived materials.49 Currently, the primary use of gelatin is 
in the food, pharmaceutical, and photographic industries.49 
In the biomedical field, gelatin is used in drug delivery 
and in some wound dressing and tissue-regeneration appli-
cations, but its use is heavily limited by its poor mechanical 
properties.49 These mechanical properties can be strengthened 
through physical cross-linking as well as chemical cross-
linking due to a large number of functional side groups that 
gelatin possesses; however, agents used to stabilize cross-
linked gelatin are often somewhat toxic to the human body.49 
Research into improving gelatin’s mechanical properties 
will need to be investigated in the future for gelatin to have 
a promising future as a primary biomaterial; but, until then, 
the most likely incorporation of gelatin will be as a composite 
with other natural or synthetic biomaterials, or as a carrier 
for drug delivery.
Fibrin
Fibrin is a 360-kD fibrinogen-derivative biopolymer involved 
in the natural blood-clotting process, enhancing cell adhe-
sion and proliferation.50 In addition to possessing excellent 
biodegradability and biocompatibility, fibrin exhibits high 
elastic and viscous properties; stiffens in response to shear, 
tension, or compression; and has excellent deformability.51 
One of the first developed fibrin-based products was fibrin 
glue (fibrin sealant). Tissucol/Tisseel™ (Baxter Healthcare) 
and Beriplast HS/Beriplast P™ (CSL Behring) are the first-
generation products of fibrin sealants marketed in Europe. 
Today, an expansive variety of products possessing different 
compositions and adhesive properties are available on the 
market. These products are broadly used for hemostasis and 
tissue-sealing applications in various surgical procedures, 
including neurosurgery and plastic and reconstructive 
surgery.52–54
Furthermore, fibrin has been utilized as a scaffold for 
the regeneration of numerous tissues, such as adipose tis-
sue, bone, cardiac tissue, cartilage, muscle tissue, nervous 
tissue, ocular tissue, respiratory tissue, skin, tendons and 
ligaments, and vascular tissue as well as a carrier vehicle 
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for bioactive molecules (drugs, antibiotics, or chemotherapy 
agents) due to its injectability and biodegradability.55–60 For 
instance, several studies have demonstrated that clinical 
application of fibrin significantly improved the healing of 
intrabony defects in chronic periodontitis.61,62 Further evi-
dence suggests that proteins interact differently with fibrin 
clots and, as a result, several cross-linking techniques are 
presently being studied to control the release profile of bioac-
tive molecules from the fibrin matrix.63 Additionally, fibrin 
matrices have been utilized as excellent cell-carrier vehicles. 
One successful example obtained by mixing keratinocytes 
with fibrin is Bioseed® (DCM Shriram Limited), a fibrin-
based product used to treat chronic cutaneous wounds.
Fibrin is natural, highly available, implantable, inexpensive, 
easy to use, and has low fibrinogen concentrations. Due to 
its porous morphology, a fibrin scaffold system is adequate 
for cell attachment, proliferation, differentiation,58,64 and as a 
release system of growth factors such as vascular endothelial 
growth factor and basic fibroblast growth factor (bFGF).60,65 
Fibrin-immobilized growth factors have been shown to 
be continuously released for several days in a controlled 
manner, making it optimal for numerous tissue-engineering 
purposes.50 Thus, autologous fibrin could prevent the com-
plications of techniques derived from the use of current 
commercial available fibrin products and should be further 
investigated. Fibrin-based scaffolds do have some limita-
tions, such as weak mechanical strength and quick degrada-
tion rates; however, these properties have been shown to be 
improved by incorporating stronger natural and synthetic 
polymers, utilizing various cross-linking methods, and uti-
lizing micro/nanospheres.50 Next-generation scaffolds will 
likely involve specific cell lines, combined with biomolecules 
and growth factors to accelerate and increase cell prolif-
eration and differentiation on immobilized scaffolds for a 
variety of tissues, and fibrin-based drug-delivery carriers and 
tissue-engineered scaffolds, including the relatively recent 
scaffold development of fibrin microspheres, nanospheres, 
microfibers, microtubes, and porous sheets, all of which will 
play a big role in regenerative medicine.50
Hyaluronic acid (HA)
HA is an essential component of the ECM and its structural 
and biological properties mediate cellular signaling, morpho-
genesis, matrix organization, and wound repair.66,67 In 1943, 
HA was first isolated from the vitreous humor by Meyer 
and Palmer.68 HA is a member of the GAG family, which 
involves linear polysaccharides consisting of alternating units 
of N-acetyl-d-glucosamine and glucuronic acid ranging in 
size from 5,000 to 20,000,000 Daltons in vivo, and is present 
in almost every tissue in vertebrates. Native sources of HA 
include rooster combs, bovine vitreous humor, and synovial 
fluids.69 HA degradation occurs in the body through free 
radicals, such as nitric oxide and matrix metalloproteinases 
found in the ECM, and then undergoes endocytosis. Further 
digestion of HA by lysosomal enzymes results in mono- 
and disaccharides, which are then converted into ammonia, 
carbon dioxide, and water.69
Recently, HA has become recognized as an important 
building block for the creation of new biomaterials for use in 
cell therapy, 3D cell culture, and tissue engineering.70–72 As HA 
is secreted at the early stage of wound healing, it has been 
extensively researched for wound-dressing applications.73,74 
HA can be recognized by receptors on a variety of cells 
associated with tissue repair, and thus presents the capability 
to stimulate angiogenesis and to regulate injury-induced 
inflammation as a free radical scavenger.75 Moreover, HA 
promotes epithelial and mesenchymal cell migration and 
differentiation, making it vital for tissue repair.75 These 
properties combined with its immunoneutral potency make 
HA an ideal biomaterial for tissue engineering.75 Moreover, 
its aqueous solubility allows for modification of HA into 
various porous and 3D structures for drug delivery. For 
example, HYAFF®11 (Anika Therapeutics, Inc.), an HA-
based product, is currently utilized as a carrier vehicle for 
a variety of growth factors, morphogens, and stem cells.76 
In a comparative study, Hunt et al reported an improved 
healing response to rhBMP-2 delivered by HYAFF®11 than 
that delivered by an absorbable collagen sponge.76 A more 
recent study indicated that HA-based materials maintain the 
potential to replace collagen-based materials as injectable soft 
tissue fillers.77 With regard to tissue engineering, HA has been 
successfully incorporated into multiple complex systems. 
For example, HA-modified poly(
D,L
-lactic acid-co-glycolic 
acid) (PLGA) scaffolds were successful in inducing cartilage 
tissue formation in terms of type II collagen expression and 
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Figure 1 Structure of hyaluronic acid (HA).
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tissue morphological characteristics.78 Additionally, high-
molecular-weight viscous HA solutions (eg, AMVISC® 
and AMVISC® PLUS, Bausch & Lomb) currently function 
as vitreous humor substitutes and as protection for sensi-
tive eye tissue during glaucoma surgery, cataract extrac-
tion, and corneal transplantation. Viscous HA solutions 
(eg, SYNVISC®, SanofiBiosurgery; and ORTHOVISC®, 
Anika Therapeutics, Inc.) are also clinically applied as 
synovial fluid substitutes to reduce pain and enhance joint 
mobility in patients with osteoarthritis.79
Moreover, HA derivatives, such as HA esters and cross-
linked HA gels, have been thoroughly researched for wound 
dressing applications. Reports suggest that these chemical 
modifications significantly reduce the degradation of HA.69,80 
For example, in the absence of enzymatic activity, benzyl HA 
esters undergo hydrolytic degradation via ester bonds, and 
the degradation time varies from 1 to 2 weeks to 2–3 months 
depending on the degree of esterification.69,80 Together, these 
studies underscore the potential of HA in combined systems 
for an array of biomedical applications, including tissue 
engineering, drug delivery, wound healing, and temporary 
implants.
Chitin/chitosan
Chitosan is another naturally derived biodegradable polysac-
charide commonly used in tissue engineering.81 Chitosan is 
a derivative of chitin – the second most abundant natural 
polymer commonly found in the exoskeletons of crustacean 
and insects as well as the cells walls of fungi.81 Chitin is 
partially deacetylated to form chitosan, which is composed 
of glucosamine and N-acetyl glucosamine linked in a β(1–4) 
manner.82 The molecular weight and the degree of deacetyla-
tion, which are essential in assessing the characteristics of 
chitosan, are reliant on the source and production process.
Chitin and chitosan are biodegraded by human enzymes, 
such as lysozymes, which disrupt the linkage between acety-
lated units and degrades chitin/chitosan to oligosaccharides.83 
The degradability of chitin/chitosan-based materials is essen-
tial for scaffold construction because it can influence cell 
behavior and tissue formation of the engineered construct.84 
However, the low mechanical resistance of chitosan makes 
it disadvantageous to be used as a supporting material in 
tissue engineering.85 To create a better mechanical profile, 
cross-linking agents are used with functional reactive groups 
to allow for bridges to be made between polymeric chains, 
optimizing the resistance and elasticity of chitosan mem-
branes.85 Further, chitin/chitosan have the ability to chelate 
with the Ca2+ or Mg2+ present in the cell wall of bacteria, thus 
destroying the entity of bacterial cell wall, and to react with 
the anionic phosphate groups of phospholipids found on the 
bacterial cell membrane by using their NH
3
+ amino group, 
thereby leading to changes in the cell membrane permeability 
and eventual release of the bacteria’s cellular contents.84,86 
These functional capabilities make chitin/chitosan-based 
materials exhibit a bactericidal effect on both Gram-negative 
and Gram-positive bacteria, giving them a broad medical 
utility in tissue engineering and biomedical applications.84,86
Specifically, chitin/chitosan-based materials have dem-
onstrated potential with regard to connective, nerve, adipose, 
and vascular tissue-engineering applications.87–89 For 
example, a silk fibroin (SF)/chitin-based scaffold was used 
to repair a musculofascial defect in the abdominal wall, 
displaying continuous integration with adjacent native tissue 
and mechanical strength similar to native tissue.88 Similarly, 
chitosan/hydroxyapatite-based scaffolds loaded with bFGF 
for periodontal tissue regeneration promoted vigorous pro-
liferation and migration in periodontal ligamental cells and 
cementoblasts.87 A more recent study produced nanosized 
chitosan/hydroxyapatite-based scaffolds via thermally 
induced phase separation and lyophilization techniques and 
found that this combination demonstrated greater compressed 
mechanical properties as compared to the pure chitosan 
scaffold – a property critical for the success of scaffolds 
Figure 2 Structure of chitin and chitosan.
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to be used as tissue-engineering scaffolds.90 Further tests 
will need to be conducted, but it is expected that this scaf-
fold will allow cell attachment and tissue growth in vivo as 
well. Taken together, these results highlight the potential of 
chitin/chitosan-based scaffolds providing a cell-favorable 
microenvironment for connective tissue healing.
Though chitosan has been widely used for bone tissue-
engineering applications due to its various favorable proper-
ties as mentioned earlier, it has a lower tensile strength and 
modulus range than those of natural bones.91,92 In an effort to 
reinforce the mechanical properties of chitosan, Tamburaci 
et al combined diatomite (diatomaceous earth), a natural 
silica material, with chitosan to produce a scaffold for bone 
tissue regeneration; they found that diatomite-reinforced 
chitosan composite membranes improved the surface area, 
roughness, swelling properties, and protein adsorption 
capacities of traditional chitosan membranes, while showing 
no cytotoxic effect in Saos-2 osteosarcoma cell line with 
excellent biocompatibility.93 Interestingly, Tamburaci et al 
also found that diatomite incorporation into chitosan scaf-
folds increased the proliferation and alkaline phosphatase 
activity of Saos-2 cells remarkably.93 Overall, diatomite-
reinforced chitosan scaffolds showed improved properties 
while maintaining the high biological activity typical of 
traditional chitosan scaffolds, illustrating the potential of 
chitosan for bone tissue-engineering applications.
Moreover, glutaraldehyde-cross-linked collagen-chitosan 
hydrogels were successfully applied to adipose tissue 
engineering. A study confirmed the in vitro viability of pre-
adipocytes (PAs) on glutaraldehyde-cross-linked collagen–
chitosan hydrogel scaffolds. Subsequently, a rat subcutaneous 
pocket assay was used to evaluate PA-seeded scaffolds 
in vivo which displayed excellent biocompatibility, formed 
adipose tissue, and induced vascularization.89 Additionally, 
chitin/chitosan-based materials have found success as bioma-
terials used in cartilage repair due to their biocompatibility 
and structural similarity with GAGs found in cartilage.12,94,95 
Recently, Lee’s group synthesized an injectable hydrogel 
consisting of methacrylated glycol chitosan and HA by 
photo-cross-linking with a riboflavin photo-initiator under 
visible light.12 This resulted in the formation of a cross-linked 
chitosan network in which high-molecular-weight HA was 
entrapped, forming a semi-interpenetrating network that pro-
vided a more chondrogenic-favorable microenvironment.12 
Likewise, these photopolymerizable hydrogels exhibit robust 
capacity as cell carrier vehicles and further emphasize the 
advantage of chitin/chitosan-based materials for tissue 
engineering.
Furthermore, chitin/chitosan-based materials have been 
incorporated successfully into cutaneous wound manage-
ment. A number of studies have reported the use of chitin/
chitosan scaffolds and membranes to treat patients with 
deep burns.96,97 Recently, novel α-chitin/silver nanoparticles 
(AgNPs) and β-chitin/AgNP composite scaffolds were tested 
for wound-healing applications.96,97 These chitin/AgNPs com-
posite scaffolds were found to possess excellent antibacterial 
activity against Staphylococcus aureus and E. coli, combined 
with good blood clotting ability.96,97 In addition, β-chitin/
AgNP composite scaffolds functioned as promising matrices 
capable of providing good cell attachment apart from their 
antibacterial activity, which suggests that these composite 
scaffolds are ideal for wound-healing applications.97
Finally, chitin/chitosan-based materials have presented 
excellent potential in drug delivery systems. For example, 
in one study, when carboxymethyl chitin nanoparticles 
were cross-linked with FeCl
3
 and CaCl
2
, they were shown 
to be nontoxic to mouse L929 cells while showing signifi-
cant antibacterial activity against Staphylococcus strains.98 
Studies indicating that chitin/chitosan-based materials may 
be used for controlled drug delivery in managing HIV are 
more exciting. In one study that focused on anti-transferrin 
and anti-bradykinin B2 antibody-conjugated chitosan nano-
particles, the investigators found that chitosan nanoparticles 
presented the potential to effectively penetrate across the 
blood–brain barrier and thus enhance the drug delivery in 
the brain to inhibit HIV replication in the neural system.99 
Another study showed that using chitosan nanoparticles 
to encapsulate conventional antiretroviral drugs targeting 
HIV led to a more efficient control of the viral proliferation 
in target T cells.100 Greater cell targeting efficiency was 
achieved, mostly due to the fact that chitosan nanoparticles 
are mildly immunogenic, making them more visible to 
the immune system, allowing for more efficient uptake by 
phagocytes.100 A separate investigation studied the effects of 
poly(lactic acid) (PLA)/chitosan nanoparticles loaded with 
lamivudine (a type 1 and type 2 HIV selective inhibitor) 
in mouse L929 fibroblast cells.101 The in vitro drug-release 
studies showed that the drug release rate from PLA/chitosan 
nanoparticles decreased when the pH of the medium changed 
from alkaline to acidic and further decreased from acidic to 
neutral, which could be a result of the repulsion between 
H+ ions and cationic groups present in the polymeric nano-
particles.101 Because it is ideal that the drug encapsulated in 
the delivery system will be protected in the stomach envi-
ronment at acidic pH and then provide sustained release in 
the intestines (neutral pH), these findings suggest that the 
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chitosan-based nanoparticles exhibit excellent potential as 
a carrier system for HIV-controlled drug delivery.
Besides HIV management, chitin/chitosan-based materi-
als can be used in cancer therapy as drug-delivery vehicles. 
For example, a pH-responsive magnetic nanocomposite was 
wrapped in chitosan for targeted and controlled drug delivery, 
and the yield product was found to be nontoxic and exhibited 
a high antitumor activity while maintaining its excellent pH 
sensitivity at pH ,6.0.102
In addition to improving the targeting and efficiency of 
cancer and HIV drug-delivery vehicles, chitin/chitosan-based 
materials have been utilized in various other delivery sys-
tems. In a very recent study, Di et al developed an ultrasound-
triggered insulin-delivery system which allows for pulsatile 
insulin release that can provide both long-term, sustained 
and fast on-demand responses.103 This system incorporated 
insulin-loaded PLGA nanocapsules encapsulated within 
chitosan microgels and, upon ultrasound treatment, the stored 
insulin can be rapidly released to regulate blood glucose 
levels.103 The research group found that in a mouse model 
of type 1 diabetes, a 30-second ultrasound administration 
could effectively achieve glycemic control for 1 week and 
concluded that this delivery system may potentially be used 
to release other therapeutics in a noninvasive and convenient 
manner.103 Moreover, Liang et al104 and Jing et al105 have 
shown that chitosan derivatives as a delivery system can 
also enhance oral tablet absorption of bioactive compounds 
and potentially allow protein and certain peptide drugs to be 
orally administrable. In addition, hydroxyethyl chitosan – a 
derivative of chitosan – has shown great potential as a drug-
delivery material for the treatment of glaucoma and other 
ocular diseases due to its great water-solubility and excellent 
biocompatibility.106 Further investigations must be carried 
out to assess any side-effect or instability of chitosan-based 
materials; however, there seems to be substantial potential 
for chitosan-derived drug-controlled-release systems.
Chitin/chitosan-based materials are widely studied for 
several different tissue-engineering applications, regenera-
tive medicine, wound healing, and drug delivery for good 
reason. They have excellent biodegradability and biocom-
patibility and has been known to have antiulcer, anti-acid, 
hypocholesterolemic action, wound-healing, antitumor, and 
hemostatic properties.107–110 Although chitin/chitosan-based 
materials tend to lack mechanical properties, they possess 
functional reactive side groups that can be cross-linked to 
make bridges between polymeric chains, optimizing the 
resistance and elasticity of these materials.85 Due to their 
unique combination of physical and chemical properties, 
chitin/chitosan can be molded relatively easily into porous 
scaffolds, and their cationic nature allows them to form 
polyelectrolyte complexes with many types of anionic GAGs, 
making them capable of modulating the activity of a variety 
of growth factors and cytokines for tissue-engineering 
purposes.85 An important property of chitin/chitosan is its 
mucoadhesive nature and its ability to open epithelial tight 
junctions, making them well-suited for drug delivery across 
nasal, intestinal, ocular, buccal, and pulmonary systems.85 
However, some challenges do exist. Chitosan is insoluble 
in most organic solvents, making delivery of hydrophobic 
drugs difficult; moreover, various methodologies to adapt 
the solubilization of chitosan, such as alkylation, acetylation, 
and carboxymethylation, all come with certain drawbacks 
and limitations.111
Overall, chitin/chitosan is a polymer that will have very 
important applications in both the industrial and biomedical 
fields of the future. Its unique chemical properties have 
recently allowed it to be studied as part of a biological 
functionalization of microelectromechanical systems, which 
will enable it to perform functions such as biorecognition, 
enzymatic catalysis, and controlled drug release, all of which 
is critical to the advancement of drug-delivery and scaffold 
technology.85
Starch
Starch is the primary energy reserve polysaccharide in plants, 
and it is present in the form of granules composed of amylose 
and amylopectin.112 Amylose is a linear polymer composed 
of glucose monomers linked through α-D-(1–4) glyco-
sidic linkages, whereas amylopectin molecules are huge, 
branched polymers of glucose known to be one of the highest 
molecular-weight natural polymers.113 Different plants have 
slightly different granule sizes, amylose/amylopectin ratio, 
mineral contents, and amount of phosphorous and phospho-
lipid contents that lead to varying starch properties.112 The 
specific characterization of starch is particularly important due 
to different swelling, solubility, gelatinization, mechanical 
behavior, enzymatic digestibility, rheological characteristics, 
and surface characteristics, which affect the way it needs to be 
processed to convert it to a more usable form such as hydro-
gels, pastes, and nanoparticles.114 Generally, the native starch 
isolated from different plants tends to have limited shear 
resistance, thermal resistance, thermal decomposition, and 
a high tendency toward retrogradation.112 These limitations 
have been overcome by combining starch with more stable, 
synthetic, thermoplastic polymers, or utilizing physical 
treatment of starch, such as heat or moisture, or utilizing 
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chemical modifications, introducing certain functional groups 
to remarkably alter its physicochemical properties, making 
starch vastly more useful in tissue engineering, drug delivery, 
and delivery of biologically active compounds.112
Among its tissue-engineering applications, starch is 
most famous for its usefulness in generating scaffolds for 
bone regeneration due to its bone-bonding behavior when 
reinforced with hydroxyapatite, good mechanical properties, 
non-cytotoxic and biocompatible nature, excellent substrate 
for cell adhesion, and thermoplastic behavior when combined 
with thermoplastic polymers.115 Lately, further improvements 
have been made to these starch-based scaffolds. In one 
recent study, Mahdieh et al synthesized a nanocomposite 
biomaterial consisting of a blend of thermoplastic starch and 
ethylene vinyl alcohol as the polymer matrix, and incorpo-
rated nano-structured forsterite and vitamin E as the ceramic 
reinforcing phase and thermal stabilizer, respectively.116 
What they found was that nanofosterite, a newly developed 
bioceramic, resulted in improved biological and mechanical 
properties, thereby reducing the degradation rate of the scaf-
fold whereas stimulating bone cell proliferation in comparison 
to the traditional starch–ethylene vinyl alcohol matrix.116
In particular, starch and PCL blends (SPCL) have gar-
nered much attention from many research groups for applica-
tion as a tissue-engineering construct.117 PCL improves the 
processability of starch, reduces its high stiffness, and can 
overcome the high moisture sensitivity of starch, which is 
one of the greatest weakness of starch as a biomaterial.118 
On the other hand, starch improves the biodegradability of 
PCL and, as the cheapest biomaterial on the planet, starch 
can substantially lower the high cost of the final product.119 
Through the appropriate blending of starch and PCL, SPCL 
can overcome limitations of both PCL and starch, whereas 
additionally allowing for control over mechanical and deg-
radative properties by adjusting the component ratio – a sig-
nificant advantage that allows it to conform to the numerous 
differing tissue-regenerative rates.120 SPCL is particularly 
effective in bone engineering because one of the greatest 
biological specifications of SPCL composites is their ability 
to enhance and stimulate osteoblast cell proliferation.117 
In fact, several different research groups have recently 
experimented with SPCL for this purpose.117 Carvalho et al 
studied the bone regeneration potential of undifferentiated 
human adipose-derived stromal/stem cells loaded in SPCL 
scaffolds for the regeneration of critical-sized mice calvarial 
defect.121 They found that SPCL was a suitable scaffold for 
bone tissue engineering, allowing for new tissue formation in 
the calvarial defect to be approximately 20% of the defect size 
after 4 weeks and 43% at 8 weeks.121 Link et al did a similar 
study of critical-sized cranial defects in male Fisher rats and 
found that the SPCL fiber mesh proved to be an effective 
osteoconductive material for bone regeneration.122 Requicha 
et al studied the in vivo behavior of a novel, double-layered 
SPCL scaffold functionalized with silanol groups (SPCL-Si) 
in a mandibular rodent model and compared the results to a 
commercial collagen membrane.123 They found that SPCL-Si 
scaffolds induced significantly higher new bone formation 
when compared to the commercial collagen membrane.123
Starch has been proposed as a possible drug-delivery 
system.124 In its hydrogel form, it can efficiently entrap drugs 
in interstitial spaces, thus protecting them from undesirable 
conditions in the human body.125 In addition, starch hydro-
gels are resistant to gastric juices, allowing for potential 
oral drug-delivery systems, and they can be modified to be 
degraded in very specific portions of the gastrointestinal 
tract, thus allowing for site-specific delivery.126 Moreover, 
physical modification of starch by retrogradation leads to the 
development of high levels of type three resistant starch – a 
very thermally stable, low solubility form of starch that makes 
it suitable for colon-specific delivery systems.124 However, 
in practice, studies on starch as a possible drug-delivery 
system have been very limited. Most of the research on 
starch as part of a drug-delivery system is theoretical, and 
scientists are still exploring the possible consequences of 
physical modification of starch on the mechanical and struc-
tural properties of hydrogels. To date, there is no conclusive 
data on this subject.
As the cheapest, most bioavailable, natural polymer, 
starch is an interesting renewable resource that may have 
many different biomedical applications.119 Starch is entirely 
biodegradable, noncytotoxic, biocompatible, and exhibits 
a high Young’s modulus with low levels of elongation at 
break.117 It is relatively easy to modify chemically, and it 
has the ability to replace some more expensive, synthetic 
polymers in the fabrication of composite biopolymers.127 
When starch is combined with PCL, SPCL exhibits addi-
tional properties, such as better processability, increased 
mechanical properties, controllable degradability, and 
enhanced osteoblastic cell proliferation whereas still being 
relatively cheap to produce.117 As the study by Requicha 
et al showed recently, functionalized SPCL-Si polymers 
induced much higher rates of bone formation as compared 
to the traditional (30:70) SPCL blend, further showing 
the potential of starch-based biopolymers as scaffolds.123 
However, research outside of bone tissue engineering has 
largely been limited, and the potential for drug delivery, 
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while theoretically studied, has been relatively unexplored as 
compared to many other natural polymers. Further research 
needs to be undertaken to exploit the abundance of starch for 
use in more than just bone tissue engineering.
Alginate
Alginate is a polysaccharide derived from the cell wall of 
brown seaweed and extracellularly in some bacteria. It is an 
anionic polymer that is biocompatible, nontoxic, and non-
inflammatory – as long as it undergoes multi-purification 
steps – but it is primarily known for its mild gelation condi-
tions, low cost, and relatively simple modifications in making 
alginate derivatives with new properties.128 In particular, 
alginate hydrogels have been prepared by various chemical 
or physical cross-linking methods for diverse applications 
in wound healing, delivery of bioactive agents, and tissue 
engineering.129 The primary drawbacks of alginate are its 
generalized lack of strong mechanical properties, poor cell 
adhesion, and its lack of degradability in mammals.128 How-
ever, by combining alginate with other biomaterials such as 
agarose and chitosan, and by partially oxidizing alginate with 
molecules like sodium periodate, scientists have managed to 
enhance its mechanical properties and degradability, confer-
ring significant promise on alginate-based biomaterials.129
Lately, there has been a surge of research in the use 
of alginate for regeneration and engineering of various 
tissues and organs in the body. One study attempted to 
create a tissue-engineered skin substitute by developing a 
fish collagen/alginate (FCA) sponge scaffold that was then 
functionalized by combining different molecular-weight 
chitooligosaccharides (COS) with the help of a cross-linking 
agent.130 What they found was that the excellent biological 
and functional properties of collagen, along with the con-
trollable porosity of sodium alginate, helped create a matrix 
for the cellular growth in skin tissue regeneration.130 The 
addition of COS to FCA, creating FCA/COS1, resulted in 
a scaffold with improved cell adhesion and proliferation, 
ECM compatibility, improved porosity and water uptake, 
and overall superior physical, mechanical, and biologic 
properties that could potentially be a candidate for skin tissue-
engineering application.130 Another study blended alginate 
with poly(ethylene oxide) (PEO), and the resulting product 
was then modified by acidification of carboxylate groups via 
trifluoroacetic acid (TFA) to produce poly(alginic acid).131 
Whereas electrospun scaffolds of sodium alginate are often 
limited in use for tissue engineering due to high solubility and 
uncontrollable degradation dynamics, the poly(alginic acid) 
exhibited an enhanced stability in the aqueous environment 
and controllable degradability by changing the duration of the 
TFA–alginate reaction, making it attractive in the production 
of biomedical devices for tissue engineering.131
Alginate – due to its favorable gelation conditions, bio-
compatibility, and relatively simple modifications – has also 
been studied for its use in bone regeneration and myocar-
dial tissue regeneration.132 One study showed that utilizing 
alginate as a dispersing agent in hydroxyapatite/chitosan 
composites helps to create more uniform pore structures 
than using just hydroxyapatite/chitosan composites.133 The 
increased pore morphology contributed to an increase in 
the elastic modulus and compressive strength of the scaf-
fold, thus substantially improving osteoblastic differentia-
tion for bone regeneration.133 In a separate study, a novel 
nano-biocomposite scaffold combining chitosan, gelatin, 
alginate, and hydroxyapatite was shown to have mechanical 
and biological properties mimicking natural bone.134 They 
found that they could take advantage of alginate’s anionic 
nature, coupled with its excellent cross-linking abilities – 
especially in the presence of multivalent cations – to produce 
an incredibly stable nanocomposite scaffold with a prolonged 
degradation time necessary for the formation of neotissue and 
the ECM.134 When it comes to tissue engineering, treatment 
of cardiac tissue is of notable interest, especially in the case 
of myocardial infarctions (MIs) where large portions of func-
tional tissue are often lost. In a study of a rat model of acute 
MI, Kim et al attempted an immediate post-MI local injection 
of alginate–chitosan hydrogel into the peri-infarct zone and 
assessed the results 8 weeks later.135 What they found was 
that this treatment promoted greater angiogenesis, increased 
recruitment of endogenous repair at the infarct zone via 
recruitment of cardiac stem cells, prevented cell apoptosis, 
induced cardiomyocyte cell re-entry, and, most importantly, 
prevented deterioration of cardiac function.135 The hydrogel-
injected animals demonstrated marked improvements after 
extensive MI and, given the simplicity of manufacturing and 
the entirely natural makeup of such a hydrogel, alginate-
based biomaterials for myocardial regeneration is likely to 
play a huge role in cardiovascular repair in the future.135 Fur-
thermore, sodium alginate has one of the largest applications 
in the field of wound healing, due in part to not only its excel-
lent bioresorbable and biocompatible nature, but also because 
of its ease of gelation and its physical cross-linking abilities, 
which is often favored over chemical cross-linking due to 
the ease with which they can be performed.132,136 One study 
formulated freeze-dried wafers combining a 75/25 sodium 
alginate-to-gelatin ratio and loaded it with silver sulfadiazine 
(a metal antimicrobial) for application on infected wounds.137 
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Sodium alginate gel was used as the main biomaterial 
primarily because it allows exchange between ions in the 
wound exudate and the dressing, thereby creating a moist 
environment that promotes healing.137 The gelatin is mixed in 
to prevent hydrated alginate from losing cation-crosslinkers 
over time, allowing the wound dressing to release the silver 
sulfadiazine over a 7-hour period, and severely reducing 
the bacterial bioburden compared to traditional wound 
dressings.137 Another study found that combining the use 
of alginate and deoxyribonucleic acid (DNA)-based gels 
resulted in a sustained release of bioactive factors such as 
outgrowth endothelial cells, as well as neuropeptides and 
growth factors for treatment of diabetic foot ulcers, leading 
to a substantially better healing outcome than the delivery of 
these bioactive factors alone.138 Moreover, in yet a different 
study, scientists found that integrating hyaluronic acid in an 
ionically cross-linked alginate matrix hydrogel promoted 
significant gap closure on dermal wound injuries compared to 
using either biomaterial alone.139 The addition of hyaluronic 
acid significantly improved the mechanical properties nec-
essary for a wound dressing whereas only very minimally 
affecting alginate gelation time, providing an effective and 
easy way to improve excisional wound injuries in a clinical 
setting. That is not to say that alginate-derived wound 
dressings have been entirely successful.139 In one study, a 
500-block randomized prospective study was done to test the 
effects of a silver-eluting alginate dressing to reduce lower-
extremity vascular surgery wound complications compared 
to a standard dry surgical dressing. They found no significant 
difference in using this silver alginate dressing in reducing 
postoperative wound complications.140 However, it is clear 
from these novel studies and others that alginate-based 
wound dressings will continue to play a significant role in the 
future as the relative ease of modifiability of alginate prop-
erties will allow researchers to explore a limitless number 
of possibilities and solutions to promote better healing.
Alginate is a widely utilized biomaterial, especially in 
regenerative medicine and in tissue engineering, due to its bio-
compatibility, mild and physical gelation process, chemical 
and physical cross-linking abilities, non-thrombogenic 
nature, and the resemblance of its hydrogel matrix texture to 
that of the ECM.132 Moreover, alginate happens to be easily 
modified into any form, such as microspheres, sponges, 
foams, elastomers, fibers, and hydrogels, thereby broadening 
the scope of application of alginate-based biomaterials, and 
it can be combined with other natural biomaterials to create 
and enhance new and existing properties.141 Due to the abun-
dance of algae in water bodies, alginate is one of the most 
prevalent natural biomaterials in the world, making it rela-
tively a low-cost and feasible biomaterial to use.142 However, 
better control of polymer properties and development of its 
tissue-interactive forms are necessary for breakthroughs in 
many tissue-engineering applications.132 The introduction 
of cell-interactive features to alginate biomaterials will 
become crucial in the future to properly produce replacement 
tissues and even organs.132 The type of adhesion ligands and 
spatial organizations in the hydrogel of alginates are key 
for proper functioning of regenerated tissues, and although 
arginylglycylaspartic acid (RGD) peptides have been used 
mostly to date as a cell adhesion ligand, multiple ligands in 
combination – along with solubility factors – will be neces-
sary to further our application of alginate-based biomaterials 
for regenerative purposes.129 For wound-healing applications, 
alginate-based gels will need to play a more active role, incor-
porating one or more bioactive agents to facilitate wound 
healing as compared to the rather passive process they play 
in current clinical applications.129 The future of alginate-based 
wound dressings hinges upon establishing more control over 
the delivery of one or more drugs, as well as their duration and 
sequence of release while considering external environmental 
changes.129 Furthering our understanding of the fundamentals 
of alginate properties will help researchers take advantage of 
the remarkable properties and bioavailability of alginate and 
utilize genetic engineering techniques to control the bacterial 
synthesis of alginate with new and improved properties, thus 
revolutionizing the use of this material.129
Silk
Silk fibers are natural biopolymers derived primarily from 
the silkworm Bombyx mori.143 The silk fiber consists of two 
parallel SF proteins, held together by a layer of silk sericin 
protein glue on the surface.144 Until recently, silk sericin has 
been deemed to be immunologically incompatible with the 
human body and has, therefore, been largely neglected as a 
biopolymer.145 However, SF has been used as a biomedical 
suture material for centuries.143 It is a semi-crystalline 
structure that has an incredible combination of mechanical 
properties, possessing very high tensile strength, coupled 
with excellent elasticity and flexibility.143 In fact, its strength-
to-density ratio is up to ten times higher than that of steel.146 
SF’s unique mechanical properties, tunable biodegradability, 
diverse side-chain chemistries, and the fact that genetic engi-
neering techniques can be used to tailor the protein, allows it 
to have a variety of novel properties, functions, and applica-
tions in the biomedical field.143 Furthermore, SF derived from 
other species in the order Lepidoptera often have other unique 
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properties, increasing their potential for biomedical use.145 
In addition, some spiders, such as Antheraea mylitta, have 
been found to produce silks that possess better cell adhesion 
and a more highly ordered crystalline structure, leading to 
increased mechanical strength and lower solubility in acidic 
solvents.145 Additionally, because SF is easily processed 
into gels, films, nanoparticles, membranes, nanofibers, scaf-
folds, and foam-like forms, they can be adapted to mimic a 
tremendous diversity of tissues in the human body.143 As a 
result, SF has lately been studied for use in several different 
applications, including almost all fields of tissue engineering, 
wound repair, drug delivery, and even as a possible bio-ink 
for 3D bioprinting.147
SF’s unique combination of elasticity, strength, and poten-
tial self-healing modifications (via cross-linking), along with 
its biocompatibility, tunable biodegradation, anti-bacterial, 
and other mechanical properties, makes it an attractive mate-
rial to include as a part of a composite scaffold for tissue 
engineering.148 Several different studies in the past few years 
have explored SF-based biomaterials for tissue engineering. 
In one study, Shao et al designed a nanostructured composite 
scaffold with the core consisting of hydroxyapatite and SF.149 
The composite fibers were fabricated by electrospinning – a 
technique used to generate nanoscale polymeric fibers using 
electrical energy – to create a nanofiber composite scaffold, 
and then subsequently compared to nanofibers of pure SF.149 
They found that the composite scaffold demonstrated a 
90-fold and 2-fold increase in initial modulus and breaking 
stress, respectively.149 Osteoblast-like cells were cultivated 
on the composite, and Shao et al found that the composite 
scaffold demonstrated increased biocompatibility, better cell 
adhesion, and proliferation as well as functionally promoted 
alkaline phosphatase and biomineralization.149 The group 
concluded that the nanostructured composite scaffold consist-
ing of a hydroxyapatite and SF core has excellent biomimetic 
and mechanical properties and has potential as a biocompat-
ible scaffold for bone tissue engineering.149 In another study, 
Tian et al utilized the same coaxial electrospinning technique 
to fabricate a nanofiber scaffold (p-PS/N) consisting of nerve 
growth factor, SF, and PLA.150 After 11 days, the PC12 cells 
(a model for neuronal differentiation) that were cultured on 
these scaffolds showed elongated neurites with lengths up to 
95 µm, leading the research group to conclude that p-PS/N 
scaffolds were able to support the attachment and differentia-
tion of PC12 cells for nerve tissue engineering.150 Another 
research group independently developed a 3D porous SF 
scaffold derived from the non-mulberry muga silkworm 
of Antheraea assamensis to examine its ability to support 
cartilage tissue engineering.151 They found that the SF scaf-
fold could generate enhanced sulfated glycosaminoglycans 
and type II collagen, and demonstrated in vivo biocompat-
ibility after 8 weeks of implantation in a subcutaneous model 
of rat, suggesting that these non-mulberry SF scaffold may be 
suitable for chondrocyte-based cartilage repair.151 Moreover, 
in a separate study, that same research group developed a 
3D-blended scaffold consisting of SF and human hair-derived 
keratin to investigate their ability to promote enhanced 
fibroblast cell adhesion and proliferation.152 They found that 
the scaffold demonstrated high porosity and interconnected 
pores, with excellent thermal, degradation, and mechanical 
properties.152 In addition, they found increased expression of 
collagen type I in cultured cells, demonstrating functional 
fibroblast proliferation, and the research group concluded 
that blended biomaterials, specifically SF and human hair 
keratin-blended scaffolds, may have a promising future 
as a dermal substitute for skin tissue engineering.152 In an 
attempt to engender enthesis (functional repair of tendons and 
ligaments), another research group, Tellado et al, engineered 
a complex scaffold consisting of biphasic SF scaffolds with 
integrated anisotropic and isotropic pore alignment, similar 
to what is found in native tendons/ligaments and bone/
cartilage, respectively.153 The scaffolds were functionalized 
with heparin, and human primary adipose-derived mesen-
chymal stem cells were cultured on the scaffold and assessed 
for their ability to deliver transforming growth factor β2 
(TGF-β2) and growth/differentiation factor 5 (GDF5).153 
This research group found that heparin functionalization 
increased the amount of TGF-β2 and GDF5 attached to the 
scaffold, leading to enhanced expression of cartilage and 
collagen II protein contents and enthesis, demonstrating that 
growth factor-loaded biphasic SF scaffolds may be useful in 
tendon/ligament repair.153
In addition to its numerous tissue-engineering appli-
cations, SF has recently been explored for its use as a 
biomaterial for skin repair due to its excellent hemostatic 
properties, low inflammatory potential, and permeability to 
oxygen and water vapor.154 Preliminary studies have even 
shown that SF film and sponge-based dressings promote 
wound healing and enhance skin regeneration compared to 
traditional hydrocolloids.154,155 Currently to date, there are 
only three SF-based medical products approved for clinical 
use in the world: SeriScaffold (Allergan Medical, Inc.) from 
the US FDA, TymPaSil (CG Bio Inc.) from the Ministry of 
Food and Drug Safety of South Korea and Sidaiyi (Suzhou 
Soho Biomaterial Science and Technology Co., Ltd) from 
the China Food and Drug Administration.156 Of these three, 
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only Sidaiyi is indicated for skin wound healing, but none of 
these three products are widely utilized in clinical practice.156 
A very recent clinical study done in 2017 by Zhang et al 
focused on developing a translational SF film for clinical 
application.156 They conducted a single-blind, parallel, con-
trolled clinical trial on 71 patients for treating donor-site 
wounds.156 Compared to the positive control Sidaiyi, the SF 
film demonstrated substantially faster wound healing, taking 
approximately 9.86 days on average to complete wound 
healing, compared to 11.35 days for Sidaiyi.156 Further, 100% 
of the patients treated with the SF film healed by Day 14, 
whereas 88.6% of patients treated with Sidaiyi healed by 
Day 19.156 Only one inflammatory reaction case and zero 
adverse reaction cases was noticed in the SF film group, 
whereas three inflammatory reaction cases and four adverse 
cases were recorded in the Sidaiyi group.156 The SF film 
group had cleaner wounds compared to the exudate-prone 
wounds of the Sidaiyi group, due to its better fluid handling 
capacity and gas permeability.156 This translational study, 
taken together with its previously successful studies on rabbit 
and porcine wound models, demonstrates that this newly 
developed SF film may indeed be safer and more effective 
than the Sidaiyi material currently available for clinical use 
in China for the treatment of skin repair and regeneration.156 
To date, many other studies have recently shown positive 
in vitro results with electrospun nanofiber SF dressings, or 
composite SF dressings, as a way to enhance the bulk proper-
ties of SF.157–161 Based on all these studies, it is clear that SF 
potentially has a very good outlook for the future.156
Besides the properties already mentioned, SF has many 
other unique and standout properties that make it excellent 
for use as a drug carrier.148 It can allow for loading of even 
the most sensitive of drugs, such as proteins and nucleic 
acids, due to its mild, all-aqueous processing conditions.148 
Moreover, SF has a diverse range of amino acids with several 
functional groups that can simplify the attachment of different 
types of biomolecules or antibodies, giving it a wide degree 
of functionalization.162 Finally, SF naturally has an intrinsic 
respond to pH changes, making it easy to control drug-release 
kinetics, and the mechanism of elimination from the body 
can easily be done by degradation via proteolytic enzymes 
in the body, leaving no likely side effects.163 Recently, most 
research groups have been investigating the mechanistic 
component of incorporating SF nanoparticulate for protein 
delivery, small-molecules delivery, and even anticancer 
delivery.164–166 These studies have been investigating prop-
erties of SF such as electrostatic interactions for loading 
efficiency, different drug-delivery mediums for controlling 
drug-release kinetics, and encapsulation efficiency, as well as 
compatibility, degradability, and drug retention.163 However, 
SF’s potential role in drug delivery has yet to be established 
due to the relative infancy of SF nanoparticulation, and 
further intensive examinations regarding SF properties and 
how to best exploit and improve those properties for drug 
delivery remains to be seen.163
Tissue-engineering techniques at present, while having 
improved vastly from years before, still fail to capture the 
complexity of the 3D anatomy and functionality of human 
tissues and, as a result, very few engineered constructs reach 
human clinical trials.147 3D bioprinting offers an untapped 
potential to capture the complexity of human tissues, 
and it has been touted as the future of tissue-regeneration 
strategies.167 One of the most crucial aspects of 3D printing 
is bio-ink design, which not only provides the 3D architecture 
but also acts as the first point of contact for cells to synthesize 
regulatory proteins and cytokines appropriate for the tissue 
it is mimicking.168 Silk has become one of the most popular 
choices for bio-ink preparations. The ability to physically 
cross-link its protein polymer chains via inter- and intramo-
lecular β-sheet semi-crystalline structure formation allows 
it to be stabilized after printing without the need for any 
chemical or photochemical reactions or additives.169 In addi-
tion, silk is a very strong and robust material as previously 
mentioned, and its inherent spinnability, cytocompatibility, 
and controllable degradability make silk a very strong 
candidate for future bio-ink preparations.147 Of course, studies 
are still in its infancy stages and, so far, reported literature 
on silk 3D bioprinting has demonstrated cell viability after 
printing to be anywhere from 45% to 98%.170 However, of 
the limited available hydrogel bio-inks currently tested, 
optimized blends of B. Mori silk–gelatin bio-inks has shown 
the most potential for 3D bioprinting of functional tissue 
equivalents.147 Significant scientific and regulatory challenges 
still remain before 3D bioprinting technology can hit com-
mercialization levels, and more experimental studies need to 
be done on optimizing silk as a potential bio-ink.147
SF-based biomaterials have immense potential as one of 
the preeminent natural biopolymers studied today. Its ease 
of structural modification, controllable degradability, high 
tensile strength, elasticity and flexibility, potential to intro-
duce physical cross-links, hemostatic and self-healing attri-
butes, and its ability to be processed into numerous different 
forms, such as sponges, films, and hydrogels, make SF a 
polymer with various biomedical applications.143 However, 
unlike starch or more bioavailable polymers, silk is produced 
by only a select number of species, and only in B. Mori are 
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they available in appreciable amounts.143 Although spider silk 
has been shown to display impressive toughness, stiffness, 
strength, and extensibility, it is impractical to obtain any large 
quantities of silk from any spider.145 One study has pointed to 
the transgenic expression of spider silk in plants (eg, tobacco 
and potato) or utilizing mammalian epithelial cells as a way 
to garner a more substantive production of silk, but so far, 
no solutions are in place.171,172 Besides sustainability, the 
key to developing new silk-incorporated biomaterials and 
to advance our current technology in tissue engineering is 
to work on surface modifications or compositing with other 
synthetic polymers and to figure out how to control crystal-
lization in SF when it is thermally treated or mechanically 
stretched.145 With novel cross-linking methods, SF-based 
materials can be designed to self-heal, which will result in 
new applications for tissue engineering and wound healing.145 
Silk sericin – the neglected protein in silk fibers – also needs 
to be studied in more depth. While it has long been deemed 
biologically incompatible with the human body, new studies 
show that silk sericin is only immunogenic when associated 
in conjunction with SF.145 When used by itself, or combined 
with other biopolymers, sericin has been shown to have 
attractive bioactive properties, with its antioxidant character, 
moisturizing ability, and mitogenic effect on mammalian 
cells.173 Its promotion of keratinocytes and fibroblasts have 
led to the development of sericin-based biomaterials for skin 
tissue repair, and its ability to be cross-linked with genipin 
can allow for it to be used in bone, dermal, and neural tissue 
engineering.174 Furthermore, sericin may be utilized for drug 
delivery because it can help facilitate the fabrication of nano- 
and microparticles, hydrogels, and conjugated molecules, 
through its chemical reactivity and pH-responsiveness, thus 
improving the bioactivity of drugs.173 Currently, methods 
of purifying silk sericin protein have been mostly met with 
unpredictable results in size, composition, and biological 
activity, but future technological advancements and recovery 
methods may lead silk sericin to be an important biomaterial 
in the field of tissue engineering and drug delivery.144
Polyhydroxyalkanoates (PHA)
PHA is a class of natural, biodegradable polyesters synthe-
sized by microorganisms as intracellular carbon- and energy-
storage compounds in uneven growth conditions.175 They 
have exceptional biodegradability and biocompatibility, and 
produce nontoxic degradation products, making them excel-
lent for use in biomedical applications such as drug delivery, 
tissue engineering, and substitute for implantable devices,176 
including sutures, repair patches slings, orthopedic pins, 
scaffold, stents, and adhesion barriers.177 However, unmodi-
fied PHAs – despite their exceptional abilities mentioned 
above – have some important limitations, such as the presence 
of large crystals causing poor mechanical properties,178 poor 
thermal stability, high hydrophobicity, and slow degradation 
rate, rendering them unfavorable to be used for many biomed-
ical applications.179 The intrinsic hydrophobicity of PHAs 
impedes their utilization in biomedical applications,177 as 
many biomedical appliances require better hydrophilicity.179 
Moreover, PHAs are lacking in chemical functionalities, and 
the polyesters are frequently incompatible when combined 
with drugs.177 Although biodegradable, PHAs are extremely 
stable when unmodified, thus diminishing their therapeutic 
functions in other areas.177 Meanwhile, uncommon PHAs 
possessing functional side groups including hydroxyl- and/or 
carboxyl groups, methylated-branches, and other hydrophilic 
derivatives have been produced by a few organisms to 
broaden the applicability of PHAs.180 Therefore, it is crucial 
that PHAs need to be modified to fix these properties while 
maintaining their exceptional characteristics to make them 
capable for use in biomedical applications.
A very important character of PHAs is that they can be 
developed in a way to have various physicochemical behav-
iors in properties such as amphiphilicity, crystallinity, and 
mechanical properties by simply choosing an appropriate 
production strain, cultivation conditions, and carbon 
sources.181,182 Because PHAs are generated by over 300 dif-
ferent types of Gram-positive and Gram-negative bacteria, 
there are numerous ways to produce different properties 
of PHAs, making PHA the largest group of biopolymers 
and, therefore, one of the most promising in biomedical 
applications.176 In addition to the biosynthesis of PHA using 
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Figure 3 Structure of poly-(R)-hydroxybutyrate (polyhydroxyalkanoate, PHA).
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different bacteria, there are several alternative approaches 
that have been developed, making PHA a vastly accessible 
biopolymer. Blending one PHA with another PHA, blending 
PHAs with other biodegradable polymers and polyesters, 
and chemical modifications of PHAs such as grafting and 
copolymerization and, recently, electrospinning,183 all allow 
easy, and more importantly, precise modulation of the PHA 
structure, leading to predictable functionalities.179 Whereas 
blending has been shown to produce properties in PHAs 
that fall within extremes, grafting and copolymerization 
have led to a development of a variety of PHAs with differ-
ent characteristics that may be used for several biomedical 
applications.179 With the advantages gained from the devel-
opment of metabolic engineering, PHAs with various com-
binations of monomers with differing proportions can be 
also produced from inexpensive substrates, such as glucose 
and fatty acids.175
PHAs have been widely studied for a vast field of bio-
material applications. For example, one study compared 
the various properties of different PHA scaffolds and their 
fabrication techniques for use in bone tissue engineering and 
posited that composite scaffolds via mixing different PHA 
materials may produce even better scaffolds.184 Another 
study specifically identified poly-3-hydroxyoctanoate – a 
type of PHA generated by Pseudomonas mendocina – as 
a PHA biomaterial that successfully showed great, distinc-
tive properties for cardiac tissue engineering.185 A different 
study studied solution-cast films and nonwoven electrospun 
membranes prepared from poly(3-hydroxybutyrate-co-4-
hydroxybutyrate) solutions as experimental wound dressings 
and found that they accelerated wound vascularization and 
the healing process.186 Another study assessed a different 
variation of PHA – a composite scaffold consisting of PHA/
ceramic composites – which showed greater bioactivity and 
bone regenerating potential both in vitro and in vivo.187
A couple of studies found that, compared to either poly(3-
hydroxybutyrate) (PHB) or poly(ethylene glycol) (PEG), 
a novel alternating block copolymer based on PHB and PEG 
(PHB-alt-PEG) had enhanced tunable mechanical properties 
and improved processability while remaining non-cytotoxic 
and thereby overcoming significant limitations mentioned 
previously of single unmodified PHAs.188 Furthermore, Loh 
et al found that, by adjusting the 3-hydroxybutyrate (3HB) to 
ethylene glycol ratio in this synthesized thermogelling PHB-
alt-PEG copolymer or the concentration of the copolymer 
in the hydrogel itself, the drug-release rates of multi-block 
PHB-alt-PEG can be easily controlled.189 Further study has 
shown that the PHB-alt-PEG system can also be used as 
a long-term drug-delivery system for a mouse model of 
hepatocellular carcinoma by changing the concentration of 
the gel, showing significant potential for further development 
in anticancer applications.190
In addition, within the last few years, discoveries regard-
ing more therapeutic applications of PHA monomers have 
emerged, including the treatment of epilepsy and neurode-
generative disorders. A study showed that increasing the 
blood concentration of 3HB – the monomer of PHB – was 
useful in controlling seizures: the mean latency to the onset 
of seizure was significantly prolonged in 3HB-treated mice, 
suggesting that the ketone body 3HB maintains potential as 
an anticonvulsant for patients with epilepsy.191 Another study 
investigating murine L929 fibroblasts, human umbilical vein 
endothelial cells, and rabbit articular cartilages demonstrated 
that 3HB had a stimulatory effect on cell-cycle progression 
that was mediated by a signaling pathway dependent upon 
increases in [Ca2+].192 Similarly, Maalouf et al found that 3HB 
significantly decreased the mitochondrial production of ROS 
and the accompanying excitotoxic changes by increasing 
nicotinamide adenine dinucleotide (NADH) oxidation in the 
mitochondrial respiratory chain, but did not affect levels of the 
endogenous antioxidant glutathione. Therefore, 3HB reduced 
glutamate-induced free radical formation by improving the 
NAD+/NADH ratio and increasing mitochondrial respiration 
in neocortical neurons.193 In the same study, 3HB in combina-
tion with acetoacetate reduced neuronal cell death and pro-
hibited changes in neuronal membrane properties. Together, 
these studies indicate that the ability to modify and design 
PHAs with a wide range of accessible properties shows great 
promise for PHAs as potential therapeutic biomaterials.
Clearly, extensive research has already been done on 
PHAs and their potential for success, but there has only 
been one FDA-approved PHA for biomedical use – poly(4-
hydroxybutyrate) – which has very high elasticity for use as 
an absorbable suture.194 Because each individually modified 
PHA needs to undergo extensive tests to prove that biocom-
patibility and biodegradability are still as exceptional as it is 
in its unmodified form, more tests need to be done for PHA 
use to be expanded. This is particularly true of composite 
PHAs, which seem to have nearly unlimited potential in 
creating diverse biomaterials with even better properties for 
their specific purpose. Furthermore, despite their enormous 
potential, commercial uptake of PHAs is limited due to the 
inconsistent polymer properties and high production costs 
of the raw polymer.195 Moreover, sustainability is another 
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significant issue. One recent article advocated that because 
substrates for PHA production can be found in carbon-rich 
waste located mostly in economically poor countries, integra-
tion of biopolymer production into these areas will provide 
both sustainable PHA production and a more extensive labor 
market for these countries.196 However, in order for such 
sustainable practice to happen, policymakers, scientists, 
and the heads of the relevant industrial branches will need 
to work together.
Sundew adhesives
Sundew adhesive is a natural polysaccharide-based hydrogel 
which was discovered when scientists began to investigate 
a carnivorous plant known for its peculiar lifestyle.197 This 
plant, the Sundew Drosera, uniquely utilizes two different 
glands: the sessile gland, which secretes digestive enzymes, 
and the stalked gland, which produces a sticky exudate to 
attract and then restrict prey from escaping.197 This sticky 
exudate produced by the latter gland has, in particular, 
garnered the interest of many researchers due to not only its 
biocompatibility, biodegradability, and eco-friendly nature, 
but also because of its antibiotic characteristics, its unique 
properties of enhancing cell adhesion and differentiation, 
and for its extremely high elasticity.198 In fact, its elasticity 
has been shown in studies to be so remarkable that it can be 
drawn into threads of approximately 1 m in length.198 Upon 
further investigation, scientists have discovered the chemical 
structure of the exudate produced by Drosera to be a bio-
adhesive formed by xylose, mannose, galactose, glucuronic 
acid, and ester sulfate in the ratio of 1:6:6:6:1.199
Studies done on the Sundew have mostly returned with 
positive findings. For example, Zhang et al found that drying 
the adhesive produced by the sundew plant allowed neuron-
like cells to attach and grow on the nanofibers made by the 
dried adhesive, showing the potential of the sundew adhesive 
for tissue engineering.199 In more recent studies, fibrous scaf-
folds obtained from the Sundew adhesive have been found 
to increase adhesion of numerous types of cells, including 
fibroblast and smooth muscle cells. It was found that nano-
networks within the sundew adhesives exhibit viscoelastic 
behaviors that allow for, among other things, more powerful 
adhesion of multiple mammalian cells.197
However, despite the promise Sundew adhesives have 
shown, some concerns have been raised that may limit the 
potential of the sundew adhesives. One study found that 
the sundew adhesives are highly susceptible to tempera-
ture variation and that adhesion strength was substantially 
diminished at temperatures between −20°C and −80°C.197 
However, a much more important issue that may overshadow 
the sundew adhesives’ therapeutic potential is the ability 
to collect sufficient quantities of the hydrogel.200 However, 
Sun et al were able to develop a sundew-inspired adhesive 
hydrogel mimicking the native sundew adhesives with 
superior adhesive strength, nanostructure, and resistance to 
shearing compared to other hydrogels in vitro, whereas also 
demonstrating superior wound-healing capabilities when 
paired with mouse adipose-derived stem cells in vivo.200 
Despite these findings, much more study needs to be done 
to see if there are more efficient methods of collecting the 
natural Sundew adhesive, and to assess the safety and efficacy 
of sundew-inspired adhesive hydrogels.
ivy nanoparticles
Ivy, which belongs to the genus Hedera, is known for the 
unique ability to affix itself to and grow upwards on surfaces 
such as rocks, trees, and fences, to name just a few.201 To do 
this, ivy has been found to use adhering disks generated by 
the stem of the Ivy plant.201 These adhering disks consist of 
four to seven tendrils or “fingers” which generate a substance 
called ivy nanoparticles (INPs).201 These INPs are entirely 
organic and are formed by a group of macromolecules 
composed of arabinogalactan proteins, and it is the INPs 
that are primarily responsible for the immense amount of 
force the Ivy can generate.202 In fact, it has been shown that 
an ivy disc weighing just 0.5 mg can produce approximately 
0.9 kg pull-off force, which is 1.8 million times larger than 
the weight of the adhering disc itself.203 This incredible 
adhesive strength – combined with their excellent aqueous 
solubility, low intrinsic viscosity, biocompatibility, and 
biodegradability – demonstrate the immense potential of 
INPs in the field of tissue engineering.14
In one recent study investigating the potential of INPs 
in drug delivery, INP-conjugated doxorubicin exhibited a 
stronger cytotoxic effect against multiple cancer cell lines 
in vitro and in vivo.14 In that same study, INPs were also 
found to allow stronger adhesion of smooth muscle cells in 
the collagen scaffolds once they were embedded with INPs, 
showing that not only can INPs be used as drug carriers for 
cancer therapy, but also as nano-fillers to enrich scaffolds.14 
In addition, INPs demonstrate unique optical properties that 
exhibit strong Ultraviolet (UV) absorbance and scattering, 
potentially allowing them to play an important role as a 
sunscreen protective agent.204 Currently, most sunscreens 
today utilize metal oxide nanoparticles as fillers; however, 
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environmental concerns, as well as safety concerns of using 
these nanoparticles on skin, make using traditional sunscreens 
less than ideal. When compared to TiO
2
 nanoparticles, which 
are the metal oxide nanoparticles used frequently in tradi-
tional sunscreens today, the ivy nanoparticles block more 
UV light, are less toxic to mammalian cells, and are more 
easily biodegradable, showing that ivy nanoparticles may 
potentially be used as a better, safer sunscreen agent.205
Considering their excellent physical profile, it is likely 
there are far more applications for these INPs. Unfortunately, 
application of INPs is severely limited due to the obscurity 
they have been in.202 In fact, the structure of INPs has only 
recently been identified. More studies need to be done to 
verify their safety and efficacy, as well as to discover a 
sustainable way to produce these nanoparticles – whether 
they are naturally derived or synthetically mimicked.202
Synthetic biodegradable polymers
Although natural polymers have demonstrated the potential 
advantage of supporting cell function and adhesion, there 
are a few limitations and concerns with regard to their 
use. For example, it is difficult to control the mechanical 
properties and degradation rates of natural polymers, and 
there exists the potential for a natural polymer to elicit an 
immune response or carry microbes or viruses.16,206 In con-
trast, synthetic polymers can be modified to possess a much 
wider range of mechanical and chemical properties than 
natural polymers. Although synthetic polymers can avoid 
problems with immunogenicity, biocompatibility poses a 
new challenge.207 Thus, degradable synthetic polymers are 
currently being studied extensively in order to avoid the 
potential long-term effects associated with non-degradable 
polymers, such as scarring and inflammation.207,208 Mean-
while, synthetic polymers can be produced under controlled 
conditions and thus exhibit predictable and reproducible 
mechanical and physical properties such as tensile strength, 
elastic modulus, and degradation rate.207 A further advantage 
of synthetic polymers is the control of material impurities. 
Lastly, pure synthetic polymers with well-defined and simple 
structures have lower possible risks with regard to toxicity, 
immunogenicity, and infections.
Saturated aliphatic polyesters
Saturated aliphatic polyesters, such as poly(glycolic acid) 
(PGA), PLA, and PLGA copolymers, are the most often used 
biodegradable synthetic polymers for 3D scaffolds in tissue 
engineering.207–211 The chemical properties of these polymers 
allow hydrolytic degradation through de-esterification. For 
example, PLA and PGA can be processed easily, and their 
degradation rates and physical and mechanical properties 
are adjustable over a wide range by using various molecular 
weights, structure, composition, and copolymers.207,208,211 
Moreover, the body contains highly regulated mechanisms 
for completely removing monomeric components of glycolic 
and lactic acids when these polyesters degrade: glycolic 
acid is converted to metabolites or eliminated by other 
mechanisms, whereas lactic acid can be cleared through the 
tricarboxylic acid cycle.212 Due to their biodegradability and 
biocompatibility, PGA and PLA have been approved by the 
FDA for use in medical devices, such as degradable sutures 
and other implantable devices.213
PGA
PGA is a hydrophilic and highly crystalline polymer with a 
relatively fast degradation rate. It degrades rapidly in aqueous 
solutions or in vivo, and loses its mechanical integrity 
between 2 and 4 weeks – depending on the molecular weight 
and the degradation conditions.212,214 Moreover, PGA has 
great flexibility in the tuning of its material properties and 
physical parameters such as pore size and tortuosity, which 
are important for developing scaffold-based tissue-engineer-
ing constructs.212,214 Thus, PGA can be used not only in tissue 
engineering, but also in wastewater treatment, food products, 
and other biomedical applications such as drug delivery or 
biological glues.215–219 Furthermore, previous studies have 
successfully developed PGA sheets combined with fibrin 
glue to treat open soft tissue wounds during oral surgery.220,221 
Similarly, PGA sheets with fibrin glue were efficient at 
prohibiting postoperative bleeding, reducing postoperative 
pain, and enhancing epithelialization during the reconstruc-
tion of bone surfaces following tumor resection in the oral 
cavity.222 However, the relatively fast degradation rate – along 
with the acidic degradation products and low solubility – 
confer inherent disadvantages and, consequently, limit the 
biomedical applications for PGA.223 Thus, ongoing research 
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Figure 4 Structure of poly(glycolic acid) (PGA).
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continues with regard to several PGA-based copolymers in 
order to bypass these obstacles.
PLA
PLA is another widely used biodegradable scaffolding mate-
rial in biomedical applications.224 Although similar in struc-
ture to PGA, PLA exhibits different chemical, physical, and 
mechanical properties due to the presence of an extra methyl 
group in its repeating units. For example, it can take months 
to years to lose the mechanical integrity of a PLA scaffold,224 
which makes PLA a more suitable biomaterial for load-
bearing applications, such as orthopedic fixation devices. 
To date, multiple PLA-based orthopedic products are avail-
able in the market, including the Phantom Soft Thread Soft 
Tissue Fixation Screw® (DePuy), Phantom Suture Anchor® 
(DePuy), Full Thread Bio Interference Screw® (Arthrex), 
BioScrew® (Conmed), Bio-Anchor® (Conmed), Meniscal 
Stinger® (Linvatec), and the Clearfix Meniscal Dart® (Inno-
vasive Devices). A novel promising biomedical engineering 
application for PLA involves photoluminescent graphene 
quantum dots (GQDs) with a large surface area and superior 
mechanical flexibility, which possess interesting optical and 
electronic properties.225 A recent study reported that the mul-
tifunctional nanocomposite of PLA and PEG-grafted GQDs 
(f-GQDs) is biocompatible with low cytotoxicity, which 
makes it suitable for simultaneous intracellular microRNAs 
(miRNAs) imaging analysis as well as gene delivery.225 These 
results underscore the potential of the extremely versatile 
multifunctional nanocomposite – f-GQDs – in biomedical 
applications of intracellular molecular analysis and clinical 
gene therapeutics.
Three forms of PLA exist: 
L
-PLA, 
D
-PLA, and a racemic 
mixture of 
D,L
-PLA. Recently, the stereoisomer 
D,L
-PLA has 
been significantly explored as a biomedical coating for ortho-
pedic material due to its high mechanical stability and excel-
lent biocompatibility.207,226,227 Furthermore, 
D,L
-PLA of low 
molecular weight can be combined with drugs such as growth 
factors, antibiotics, or thrombin inhibitors to establish a locally 
acting drug-delivery system.9 Thus, recent efforts have shifted 
focus toward applying 
D,L
-PLA as a scaffold material for tissue 
engineering due to these highly desirable features.
PLGA
PLGA with varying lactide/glycolide ratios can be synthe-
sized to achieve intermediate degradation rates between 
PLA and PGA. Generally, the copolymer PLGA is favored 
in comparison with its constituent homopolymers for the 
development of bone substitute constructs because PLGA 
offers greater control of degradation properties by varying 
the ratio between its monomers.228 For example, PLGA 
possesses a wide range of degradation rates dictated by the 
composition of chains, hydrophobic/hydrophilic balance, 
and crystallinity.228 However, despite biocompatibility, the 
clinical application of pure PLGA for bone regeneration is 
hindered by low osteoinductivity and suboptimal mechanical 
properties for load-bearing applications. Thus, PLGA is 
typically used in conjunction with other materials, such as 
ceramics or bioactive glass, and is routinely modified in order 
to render it more biomimetic, thereby improving its ability to 
enhance bone regeneration.229 By implanting AgNP/PLGA 
composite grafts into grossly infected critical-sized bone 
segmental defects, our group demonstrated that AgNP/PLGA 
composite grafts possess significant antibacterial properties 
and osteoconductivity in vivo.209 In a follow-up experiment, 
we unexpectedly found that AgNP/PLGA-coated stainless 
steel alloy materials not only exhibited strong antibacterial 
activity but also presented significant osteoinductivity that 
was not observed in their individual components alone.210 
Similarly, Shi et al reported that PLGA/hydroxyapatite 
microsphere composites with the bisphosphonate-based 
osteoporosis-preventing drug alendronate significantly 
inhibited the growth of macrophages, which have been iden-
tified as precursors of osteoclasts and as being potentially 
responsible for osteoporosis, while improving osteoblast 
proliferation and upregulating the expression of a key 
osteogenic enzyme – alkaline phosphatase.230 Together, 
these findings require more research into the osteoconduc-
tive and osteoinductive properties of PLGA-based systems 
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Figure 5 Structure of poly(lactic acid) isomers (l-PLA, d-PLA, d,l-PLA).
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but, nevertheless, offer promising therapeutic material for 
orthopedic surgery.
Poly(ε-caprolactone) (PCL)
PCL is another saturated aliphatic biodegradable polyester 
used in the development of tissue-engineering scaffolds and 
other biomedical applications.231–233 PCL is a semi-crystalline 
polymer with a melting temperature of 55°C–60°C and a very 
low glass-transition temperature of approximately −54°C and, 
thus, it tends to maintain a rubbery state and high material 
permeability under physiological conditions.231–233 It can be 
degraded by microorganism, hydrolytic, enzymatic, or intrac-
ellular mechanisms under physiological conditions; however, 
PCL’s slow degradation rate of 2–4 years, compared to PLA, 
PGA, and PLGA, along with its hydrophobicity makes it less 
attractive for general tissue-regeneration applications and 
more attractive for long-term implants and drug-delivery 
systems.234,235 A recent study demonstrated that gravity-spun 
collagen-coated PCL fibers enhanced proliferation rates of 
human osteoblast cells.234 Accordingly, these findings under-
score the potential of gravity-spun PCL fibers as a delivery 
platform for ECM proteins to enhance cell adherence and 
proliferation for tissue repair. Similarly, PCL has been used 
to effectively entrap antibiotic drugs and, subsequently, was 
incorporated into a drug-delivery system for enhancing bone 
ingrowth and regeneration in the treatment of bone defects.236 
Moreover, ongoing research continues regarding micro- and 
nanoscale drug-delivery vehicle systems centered on PCL.237 
Additionally, a solid, freeform, fabrication-based injection 
molding process has been developed for the fabrication of 
PCL, and the resulting PCL–calcium phosphate scaffolds 
display in vitro cytocompatibility and suitable mechanical 
properties for hard tissue repair.238 Further, Chiari et al have 
reported the viability of using a composite matrix composed 
of PCL and HA as a possible meniscus substitute.239 Overall, 
PCL is a useful biodegradable biomaterial deserving further 
investigation as a porous scaffold for bone tissue engineering 
and as a drug-delivery vehicle.
Polyanhydrides
PLA, PGA, and PLGA possess immense utility for drug 
delivery, but they do have limitations, including a tendency 
for a non-uniform release profile with certain drugs. Thus, 
in response to these problems, polyanhydrides were created. 
Polyanhydrides were initially designed for drug-delivery 
applications due to their hydrophobicity and ability to 
undergo degradation through surface erosion rather than 
bulk degradation, which allows for a constant release profile 
for certain drugs and is especially important in the case of 
extremely potent drugs.240 Polyanhydrides are biocompatible 
and degradable in vivo into nontoxic diacid byproducts, 
which are eliminated from the body as metabolites.240 For 
these reasons, drugs can be well protected when implanted in 
such polymers due to the fact that almost no water penetrates 
before the polymer erodes.241 Therefore, in 1996, polyanhy-
drides were approved as a drug-delivery vehicle by the FDA 
following comprehensive drug release and biocompatibility 
evaluations.242
Generally, polyanhydrides can be easily synthesized from 
widely available, low-cost sources and have been modified 
to possess desirable characteristics.243 Poly[(carboxyphenoxy 
propane)-(sebacic acid)] is the most widely investigated 
FDA-approved polyanhydride. It is typically utilized as a 
localized delivery vehicle, specifically for the controlled 
delivery of the chemotherapeutic agent bis-chloroethyl 
nitrosourea during brain cancer treatment (Gliadel®, Arbor 
Pharmaceuticals, LLC).244 Moreover, the results of previous 
PLGA
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Figure 6 Structure of poly(lactic acid-co-glycolic acid) (PLGA). X=number of units 
of lactic acid and Y=number of units of glycolic acid.
Figure 7 Structure of poly(e-caprolactone) (PCL).
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Figure 8 Structure of polyanhydride.
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animal studies were validated in a recent human trial, veri-
fying the promising potential of this polymer drug-delivery 
system.244 Clearly, future exploration of polyanhydrides in 
drug-delivery systems is warranted.
Polyurethane (PUR)
Owing to their toughness, durability, biocompatibility, 
and biostability, PURs are a favorable choice for medical 
devices and, since the 1960s, they have been utilized 
typically as biostable and inert materials in heart valves, 
vascular grafts, catheters, and prostheses.245,246 However, 
in the late 1990s, interest regarding the design of biode-
gradable PURs for tissue engineering and drug delivery 
surged due to their relative sensitivity to biodegradation 
as well as the desire to further understand the biological 
mechanisms for in vivo biodegradation.246 Biodegradable 
PURs possess convincing potential as scaffolds for tissue 
regeneration.245,246 They exhibit a broad range of versatility 
in terms of modifiable mechanical properties, biological 
properties, physical properties, biodegradability, and blood 
and tissue compatibility due to their segmented-block 
structural character.
PURs are normally synthesized through a polycondensa-
tion reaction of diisocyanates with alcohols/amines, whereas 
the synthesis of biodegradable PURs allows for the incor-
poration of hydrolyzable segments into their backbone.247 
Nevertheless, the toxicity of common diisocyanates such 
as toluene diisocyanate and 4,4′-methylenediphenyl diiso-
cyanate has led to the consideration of other biocompatible 
aliphatic diisocyanates for developing a new generation of 
biodegradable PURs. Recently, the development of bio-
compatible aliphatic diisocyanates and amino acid-derived 
diisocyanates possessing reduced toxicity, such as lysine 
diisocyanate and 1,4-diisocyanatobutane, has allowed for 
novel opportunities to synthesize biocompatible and bio-
degradable PURs that can enhance cell proliferation and 
adhesion without adverse effects.247 Moreover, a biodegrad-
able elastic PUR – Degrapol® (Abmedica) – is currently 
being used to develop a highly porous scaffold for tissue- 
engineering applications.248 It is also worth noting that a 
unique, injectable, two-component lysine–diisocyanate-
based PUR system – PolyNova® (PolyNovo Biomaterials 
Pvt. Ltd) – has been developed for orthopedic applications.249 
PolyNova® polymerizes at physiological temperature in situ 
and, thus, arthroscopic administration in its liquid form results 
in suitable mechanical support and comparable or superior 
bonding strength relative to standard bone cement. Addition-
ally, it supports favorable cell adhesion and proliferation.249 
Together, the research indicates the promising potential for 
PURs in various biomedical applications, such as porous 
scaffolds for tissue engineering and drug delivery.250
Polyphosphazenes
Polyphosphazenes are a relatively newer class of inorganic–
organic hybrid polymers composed of an inorganic backbone 
of repeating phosphorus and nitrogen atoms with alternating 
single and double bonds. To date, polyphosphazenes have 
been investigated as potential biodegradable biomaterials 
due to their synthetic flexibility, unparalleled functionality, 
and adaptability for numerous applications.
The phosphorous–nitrogen backbone of polyphospha-
zenes confers extraordinary flexibility, whereas their side 
groups determine the different properties of these polymers. 
Considering these features, polymers possessing highly 
controlled properties including solubility, hydrophobicity/
hydrophilicity, extent of crystallinity, and appropriate 
thermal transitions can be designed and developed through 
modification of their side groups.251 Furthermore, the 
degradation profiles of the polymers can be controlled 
by modifying their side groups to achieve appropriate 
degradation profiles ranging from a few hours to years.251 
Laurencin et al studied different poly[(amino acid ester) 
phosphazenes] and revealed that polyphosphazenes showed 
the fastest degradation after modification with glycine ethyl 
ester.252 In contrast with polyesters, the poly[(amino acid 
ester) phosphazenes] degrade into neutral and nontoxic 
products such as ammonia, phosphates, and the correspond-
ing ester side groups.252 Taking advantage of this unique 
property, a recent study combined polyphosphazenes 
with PLGA to form self-neutralizing blend systems.253 In 
addition, polyphosphazenes are suitable for drug delivery 
with their distinct ability to undergo both surface and bulk 
erosion while maintaining controllable rates and modes of 
degradation.254
Figure 9 Structure of polyphosphazene.
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With regard to biocompatibility and toxicity, the majority 
of the poly[(amino acid ester) phosphazenes] implanted sub-
cutaneously elicited minimal to mild tissue responses.251,255–257 
Furthermore, several of the poly[(amino acid ester) phosp-
hazenes] have demonstrated significant osteoconductivity 
and have been explored as matrices for bone tissue 
engineering.251,255 Recently, by utilizing the advantageous 
interactions between polyphosphazene side groups and 
calcium phosphate ceramics, a polyphosphazene-self set-
ting calcium phosphate composite cement system was 
created.258 However, as a result of the flexible backbone, 
many of the poly[(amino acid ester) phosphazenes] are 
soft elastomeric polymers and, thus, present limitations as 
a biomaterial used for load-bearing applications. Addition-
ally, a recent study found success in using a glycine-based 
photo-polymerizable polyphosphazene as a scaffold for 
adipose tissue regeneration.259 Preliminary results demon-
strated the non-cytotoxic nature of the polymers and their 
degradation products and the cell adhesion and proliferation 
of adipose-derived stem cells.259 Meanwhile, another report 
suggests that blends with PLGA may benefit the application 
of polyphosphazenes in osteogenesis. The initial hydrolytic 
degradation of PLGA generates a porous structure with some 
residual strength, which would then degrade over a much 
longer period of time. Therefore, fine-tuning the system 
could potentially yield biomaterials with tissue-engineering 
properties superior to those of PLGA.260 However, their utility 
as scaffolds in tissue engineering is still under investigation 
and warrants further studies.
In truth, with regard to on-the-market applications and 
clinical studies, polyphosphazenes are severely lacking 
compared to the more established polymers for drug-delivery 
applications. However, the many promising in vitro and in 
vivo studies spanning a broad range of therapies highlights the 
potential of polyphosphazenes in this area.251–260 Furthermore, 
the inherent high functionality of the phosphorus–nitrogen 
backbone along with the intrinsic, tunable, biodegradability 
of polyphosphazenes251 underscores their immense potential 
as a group of biomaterials for drug delivery and other bio-
medical applications.
Conclusion
Due to the presence of a wide diversity of biomaterials, 
both natural and synthetic, varying quality of material 
formulation, and a general lack of comparative studies of 
different biomaterials for specific biomedical applications, 
it is impossible to conclude which polymer is the most 
ideal. In general, natural biomaterials have greater inherent 
biocompatibility compared to synthetic biomaterials, but they 
are also mechanically inferior, as their mechanical, structural, 
and chemical properties cannot be altered in the same way 
as synthetic biomaterials.
However, instead of trying to categorize specific poly-
mers for specific biomedical applications, it seems that 
the future of biopolymer application is to utilize different 
combinations of polymers to develop hybrid polymers 
that have a better specificity profile for specific biomedical 
applications – be it for tissue engineering, drug delivery, or 
wound healing. Indeed, numerous recent studies regarding 
polymers for biomedical use have addressed combining dif-
ferent biomaterials, via techniques like blending, grafting, 
and chemical cross-linking reactions, and the results have 
been mostly positive. With techniques like electrospinning – 
which allows for the creation of various different forms of 
nanoscale polymers, such as nanotubes, nanofibers, and 
nanospheres – combined with the nearly limitless potential 
of generating numerous different combinations of natural 
and synthetic biomaterials, there exists a very good chance 
that more effective biomaterial-based materials can be 
fabricated with the proper biocompatibility, degradation, 
and physicochemical properties for a specific biomedical 
application. Numerous challenges still exist today across 
most or all biomaterials, such as the feasibility of mass 
production at a relatively low cost as well as overcoming 
certain physiochemical limitations of specific biomaterials; 
however, with the advent of cloning and genetic engineering 
techniques to express both native and synthetic biomaterials 
in a variety of host systems, there remains a bright future for 
biopolymeric use in medicine.
Currently, in the field of tissue engineering, temporary, 
artificial composite scaffolds are being researched and 
developed for cells to adhere to, differentiate, and form new 
tissue. However, there is an increased interest in developing 
3D scaffolds that can not only support tissue regeneration, 
but also act as a biomatrix that can support cues and signals 
to promote functional tissue connections.145 One increas-
ingly popular way to generate such a scaffold is to utilize 3D 
bioprinting techniques, incorporating polymeric biomaterials 
as the bio-ink. This technology will allow us to have more 
control in the scaffold properties that were traditionally very 
difficult or impossible to control, such as cell distribution, 
fluid flow, and porosity. These resulting 3D-engineered con-
structs will allow us to mimic the properties of tissue in the 
human body better than any other traditionally engineered 
approach, making it more desirable for tissue regenera-
tion. The ultimate goal of 3D bioprinting is to eventually 
be able to develop patient-specific tissues and organs, and 
although several technical, scientific, regulatory, and even 
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ethical challenges still exist, there has been an exponential 
increase in research and interest into making such a technol-
ogy a reality.
Drug-delivery systems traditionally are either orally 
administered or injected, but problems exist in using such 
methods for protein and nucleic acid delivery. Furthermore, 
traditional drug-delivery systems still face problems with 
drug side effects, efficacy, and patient compliance. Recently, 
the use of nanotechnology has ushered in a novel strategy 
for drug delivery. Utilizing nanotechnology has led to the 
development of numerous novel carriers that are capable 
of releasing not only a wider range of molecules, proteins, 
peptides, and nucleic acids, but also allows for a more spe-
cific targeted delivery with controlled release. Nanoparticles 
based on biodegradable and biocompatible polymers, in 
particular, have recently shown potential in cancer therapy 
and as sustained drug-delivery vehicles, prolonging drug 
half-life, improving solubility, and reducing immunogenicity. 
Furthermore, they have shown the ability to simultaneously 
co-deliver multiple drugs, making patient compliance more 
likely whereas also enhancing potential synergistic effects of 
certain drugs and suppressing drug resistance. These biode-
gradable and biocompatible polymeric-based nanoparticula-
tion can also be applied in wound-healing applications via 
delivery of bioactive agents. Current clinical wound-healing 
applications play a much more passive role, and development 
of this technology will help with better, more efficient wound 
healing. Nanosized particles for drug delivery clearly dem-
onstrate significant advantages over traditional drug-delivery 
systems, and the key to future development of drug-delivery 
systems is the increased understanding and application of 
nanotechnology.
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